Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | GUCY1A1 | Q02108 | 13/20 | 0.57 |
| ▸ | GUCY1B1 | Q02153 | 13/20 | 0.57 |
| ▸ | PDE5A | O76074 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethyl Sulfoxide SCHEMBL15152548 | 0.96 | ADORA3 (0.66) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Dimethylformamide SCHEMBL18988793 | 0.93 | ADORA3 (0.68) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL18212217 | 0.92 | ADORA3 (0.70) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Formic Acid SCHEMBL15732782 | 0.92 | ADORA3 (0.63) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL29379641 | 0.90 | ADORA3 (0.73) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL248358 | 0.90 | ADORA3 (0.73) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL5472954 | 0.89 | ADORA3 (0.67) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL12630446 | 0.89 | ADORA3 (0.67) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Hydrochloric Acid SCHEMBL28612648 | 0.89 | ADORA3 (0.72) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL15732812 | 0.89 | ADORA3 (0.64) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2020210707-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-10-15 | — | — | WO | claimed |
| EP-2387404-B1 | Sgc stimulators and activators in combination with pde5 inhbitors for the treatment of erectile dysfunction | BAYER IP GMBH (DE) | 2014-06-25 | — | — | EP | claimed |
| EP-2504335-B1 | Process for the purification of methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}-carbamate | BAYER IP GMBH (DE) | 2013-09-04 | — | — | EP | claimed |
| US-8501945-B2 | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate and its purification for use as pharmaceutically active compound | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-06 | — | — | US | claimed |
| US-20120316183-A1 | NOVEL SOLVATES OF METHYLCARBAMATE | Bayer Intellecutal Property GmbH (DE) | 2012-12-13 | — | — | US | claimed |
| EP-2531187-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | Bayer Intellectual Property GmbH (DE) | 2012-12-12 | — | — | EP | claimed |
| US-8304406-B2 | Compounds for treating pulmonary hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | claimed |
| EP-2504335-A2 | METHOD FOR PRODUCING METHYL-{4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL} CARBAMATE AND ITS PURIFICATION FOR USE THEREOF AS PHARMACEUTICAL SUBSTANCE | Bayer Intellectual Property GmbH (DE) | 2012-10-03 | — | — | EP | claimed |
| EP-2504334-A2 | METHOD FOR PRODUCING METHYL-{4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL CARBAMATE AND ITS PURIFICATION FOR USE THEREOF AS PHARMACEUTICAL SUBSTANCE | Bayer Intellectual Property GmbH (DE) | 2012-10-03 | — | — | EP | claimed |
| WO-2011064171-A2 | METHOD FOR PRODUCING METHYL-{4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL CARBAMATE AND ITS PURIFICATION FOR USE THEREOF AS PHARMACEUTICAL SUBSTANCE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | claimed |
| WO-2011064156-A2 | METHOD FOR PRODUCING METHYL-{4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL} CARBAMATE AND ITS PURIFICATION FOR USE THEREOF AS PHARMACEUTICAL SUBSTANCE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | claimed |
| US-20100113452-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2010-05-06 | — | — | US | claimed |
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020210707-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-10-15 | — | — | WO | disclosed |
| US-9096592-B2 | Bicyclic aza heterocycles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| EP-2010173-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | Bayer HealthCare AG (DE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007118602-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2007-10-25 | — | — | WO | disclosed |
| CN-1330649-C | Carbamate-substituted pyrazolopyridines | BAYER AG (DE) | 2007-08-08 | — | — | CN | disclosed |
| CN-1665811-A | Carbamate-substituted pyrazolopyridines | BAYER AG (DE) | 2005-09-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316183-A1 | NOVEL SOLVATES OF METHYLCARBAMATE | KDM2B, ADH5, ADH1C | ADORA3 3527/4885KCNH2 794/4885GUCY1A1 2692/4885 |
| US-20100113452-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | PTGIR, PTGIS, EDNRB | ADORA3 128/4885KCNH2 265/4885GUCY1A1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.